SCWorx Corp (WORX) Fair Value & Analysis
Healthcare · US · Market cap $640K
Fair value as of: Jun 25, 2026
Analysis
SCWorx Corp (WORX) currently trades at $0.6036, while our model-based Fair Value estimate is $0.6931 — implying the stock looks roughly 14.8% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
About the company
SCWorx Corp., together with its subsidiaries, provides data content and services related to the repair, normalization and interoperability of information for healthcare providers in the United States. The company develops and markets healthcare information technology solutions and associated services that improve healthcare processes and information flow within hospitals and other healthcare facilities. Its software modules perform separate functions; electronic medical record management; charge description master management; contract management; request for proposal automation; integration of acquired businesses; rebate management; big data analytics model; and data integration and warehousing. The company sells its solutions and services to hospitals and health systems through a direct sales force, and distribution and reseller partnerships. SCWorx Corp. is based in Middleton, Massachusetts.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is SCWorx Corp (WORX) undervalued?
What is the fair value of WORX?
What is the quality score of WORX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.